

Please type a plus sign (+) inside this box →

+

10-12-00

Box 508

A

10/11/00

<b>UTILITY</b> <b>PATENT APPLICATION</b> <b>TRANSMITTAL</b> <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	BB1165 US NA
	First Named Inventor or Application Identifier	
	REBECCA E. CAHOON	
	Express Mail Label No.	EL073740935US
Express Mailing Date		October 11, 2000

### APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- |  |  |
|--|--|
| <p>1. <input checked="" type="checkbox"/> Fee (Authority to charge deposit account below.)<br/>(Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages <b>28</b>]<br/>(preferred arrangement set forth below)</p> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross References to Related Applications (if needed)</li> <li>- Statement Regarding Fed sponsored R &amp; D (if needed)</li> <li>- Reference to Microfiche Appendix (if filed)</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <b>3</b>]</p> <p>4. <input type="checkbox"/> Oath or Declaration [Total Pages <b>0</b>]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))<br/>(for continuation/divisional with Box 14 completed)</p> <p>i. <input type="checkbox"/> <b>DELETION OF INVENTORS</b><br/>Signed Statement below at 15 deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is checked)<br/>The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p> | <p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p>a. <input checked="" type="checkbox"/> Computer Readable Copy</p> <p>b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)<br/><b>SEQUENCE LISTING - 15</b></p> <p>c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p> <p><b>DECLARATION IN ACCORDANCE WITH 37 CFR 1.821</b></p> |
|--|--|

### ACCOMPANYING APPLICATION PARTS

8. ☐ Power of Attorney
9. ☐ Information Disclosure Statement (IDS)/Cover Letter plus PTO-1449 ☐ Copies of IDS Citations
10. ☒ Preliminary Amendment
11. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
12. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
13. ☐ Other:

14. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No.: PCT/US99/08791

15. ☐ **DELETION OF INVENTOR(S) STATEMENT:** This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the name(s) of the following person or persons who are not inventors of the invention being claimed in this application:

16. ☐ Amend the specification by inserting before the first line the sentence:  
-- This is a ☐ continuation-in-part, ☐ continuation, ☐ division of Application No. \_\_\_\_\_ filed \_\_\_\_\_, now abandoned. --

17. ☐ Cancel in this application original claims \_\_\_\_ of the prior application before calculating the filing. (At least one original independent claim must be retained for filing purposes.)

18. ☐ Priority of foreign Application No. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_  
\_\_\_\_\_ is claimed under 35 U.S.C. 119.  
(country)

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	<b>TOTAL CLAIMS</b> (37 CFR 1.16(c))	17 - 20 =	0	x \$ 18 =	0
	<b>INDEPENDENT CLAIMS</b> (37 CFR 1.16(b))	5 - 3 =	2	x \$ 80 =	\$ 160.00
	<b>MULTIPLE DEPENDENT CLAIM(S )</b> (if applicable)			+ \$ 270 =	270.00
				<b>BASIC FEE</b> (37 CFR 1.16(a))	+ \$ 710.00
				<b>TOTAL =</b>	\$ 1140.00

19. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. ☒ Fees required under 37 CFR 1.16.

b. ☒ Fees required under 37 CFR 1.17.

20. ☐ Other:

JCE41 U.S. PTO  
09/686522



### 21. CORRESPONDENCE ADDRESS

NAME	Thomas M. Rizzo				
ADDRESS	E. I. du Pont de Nemours and Company				
	Legal - Patents				
	1007 Market Street				
CITY	Wilmington	STATE	Delaware	ZIP CODE	19898
COUNTRY	U.S.A.	TELEPHONE	302-892-7760	FAX	302-892-1026

### 22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

NAME	Thomas M. Rizzo	REG. NO.: 41,272
SIGNATURE	<i>Thomas M. Rizzo</i>	
DATE	<i>Oct 11/2000</i>	

COPY TO: 22893

\\DPLRS06\SHARED\Patent Documents\Ag Products\BB-10xx-BB-11xx\BB-1165\BB1165 US NA TRANSMITTAL.doc

EXPRESS MAIL LABEL NO. EL073740935US  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the Application of:

S. ALLEN ET AL.

CASE NO.: BB1165 US NA

APPLICATION NO.: UNKNOWN

GROUP ART UNIT: UNKNOWN

FILED: CONCURRENTLY HERewith

EXAMINER: UNKNOWN

FOR: PHYTIC ACID BIOSYNTHETIC ENZYMES

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Before examination of the above-referenced application, please amend the application as follows:

**IN THE SPECIFICATION**

On page 1, lines 3 and 4, replace the sentence with:

**--CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a continuation of International Application No. PCT/US99/08791, filed April 22, 1999, now pending, which claims priority benefit to U.S. Provisional Application No. 60/082,960, filed April 24, 1998.--

**IN THE CLAIMS**

Cancel claims 1-15.

Add the following claims:

16. An isolated polynucleotide comprising:

(a) a nucleotide sequence encoding a polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 80% identity based on the Clustal alignment method, or

(b) the complement of the nucleotide sequence.

17. The polynucleotide of Claim 16, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 90% identity based on the Clustal alignment method.

18. The polynucleotide of Claim 16, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 95% identity based on the Clustal alignment method.

19. The polynucleotide of claim 16 comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.

20. The polynucleotide of claim 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.

21. The polynucleotide of claim 16, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

22. An isolated polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 80% identity based on the Clustal alignment method.

23. The polypeptide of Claim 22, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 90% identity based on the Clustal alignment method.

24. The polypeptide of Claim 22, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8 have at least 95% identity based on the Clustal alignment method.

25. The polypeptide of claim 22, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8.

26. The polypeptide of claim 22, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

27. A chimeric gene comprising the polynucleotide of claim 26 operably linked to a regulatory sequence.

28. A vector comprising the polynucleotide of claim 26.

29. A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 26.

30. The cell produced by the method of claim 29.

31. An isolated polynucleotide comprising a nucleotide sequence comprised by the polynucleotide of claim 26, wherein the nucleotide sequence contains at least 30 nucleotides.

32. An isolated polynucleotide comprising:

(a) a nucleotide sequence encoding a polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 80% identity based on the Clustal alignment method, or

(b) the complement of the nucleotide sequence.

33. The polynucleotide of Claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 90% identity based on the Clustal alignment method.

34. The polynucleotide of Claim 32, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 95% identity based on the Clustal alignment method.

35. The polynucleotide of claim 32 comprising the nucleotide sequence of SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19.

36. The polynucleotide of claim 32, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20.

37. The polynucleotide of claim 32, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

38. An isolated polypeptide, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 80% identity based on the Clustal alignment method.

39. The polypeptide of Claim 38, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 90% identity based on the Clustal alignment method.

40. The polypeptide of Claim 38, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20 have at least 95% identity based on the Clustal alignment method.

41. The polypeptide of claim 38, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20.

42. The polypeptide of claim 38, wherein the polypeptide is a myo-inositol-1 (or 4)-monophosphatase.

43. A chimeric gene comprising the polynucleotide of claim 32 operably linked to a regulatory sequence.

44. A vector comprising the polynucleotide of claim 32.

45. A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 32.

46. The cell produced by the method of claim 45.

47. An isolated polynucleotide comprising a nucleotide sequence comprised by the polynucleotide of claim 32, wherein the nucleotide sequence contains at least 30 nucleotides.

09:53:23 10/10/2023

**REMARKS**

Claims 1-15 have been cancelled, and claims 16-47 have been added. Claims 16-47 are pending. It is respectfully requested that the amendments above be entered before examination of the application.

Support for sequence identities of 80%, 90%, and 95% is found on page 6, lines 29-34 of the specification. Support for the Clustal alignment method is found on page 6, lines 36-39 of the specification. Support for claims 31 and 47 is found on page 7, lines 11-15 of the specification.

Please charge the necessary fees to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company). If the fee is insufficient or incorrect, please charge or credit the balance to the above-identified account.

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



THOMAS M. RIZZO  
ATTORNEY FOR APPLICANTS  
REGISTRATION NO. 41,272  
TELEPHONE: 302-892-7760  
FACSIMILE: 302-892-1026

Dated: October 11, 2000

TITLE

## PHYTIC ACID BIOSYNTHETIC ENZYMES

This application claims the benefit of U.S. Provisional Application No. 60/082,960, filed April 24, 1998.

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding phytic acid biosynthetic enzymes in plants and seeds.

BACKGROUND OF THE INVENTION

*Myo*-inositol 1,2,3,4,5,6-hexaphosphate, commonly known as phytic acid, is an abundant molecule in many plant seeds and vegetative tissue such as roots and tubers (Hartland and Oberlaeas (1986) *J. Assoc. Off. Anal. Chem.* 69:667-670). Phytic acid exists primarily as mixture of potassium, calcium, iron, zinc and magnesium phytate salts (Pernollet J. C. (1978) *Phytochemistry* 17:1473-1480).

In corn (*Zea mays L.*), 90% of the phytate is deposited in protein bodies localized in the germ whereas in legume crops 90% of the phytate is localized in the endosperm and cotyledons. Up to 80% of phytate is in the aluerone layer of wheat (*Triticum aestivum Lam.*) and rice (*Oryza sativa L.*) (O'Dell B. L. et al. (1972) *J. Agric. Food Chem.* 20:718-721). The presence of phytate phosphorous in such food crops decreases the bioavailability of zinc by forming a very stable insoluble phytate zink complex, making the zinc unavailable in the intestinal mucosa of mammals (O'Dell, B. L., et al. (1972) *J. Agr. Food Chem.* 20:718-721). Although phytate phosphorous is readily available to ruminants, it is poorly available to monogastric animals. In addition to being only partially digestible, the presence of phytic acid in food crops leads to excretion of other limiting nutrients such as essential amino acids, calcium and zinc (Mroz, Z. et al. (1994) *J. Animal Sci.* 72:126-132; Fox et al., In Nutritional Toxicology Vol. 3, Academic Press, San Diego (1989) pp. 59-96).

Phytic acid is thought to arise in plants by two pathways. The first pathway uses free *myo*-inositol as the initial substrate, with subsequent phosphorylation by a phosphoinositol kinase. Contribution to the free *myo*-inositol pool is either by recycling from other pathways or by the dephosphorylation of *myo*-inositol-1-phosphate. The alternate pathway uses *myo*-inositol-1-phosphate as the initial substrate, with subsequent phosphorylations catalyzed by phosphoinositol kinase. The committed step for *myo*-inositol-1-phosphate production is the NAD<sup>+</sup>-catalyzed oxidation of carbon 5 of the b-enantiomer of D-glucose-6-phosphate. This reaction is catalyzed by *myo*-inositol-1-phosphate synthase (Raboy, V. In Inositol Metabolism in Plants (1990) Wiley-Liss, New York, pp. 55-76).

Phytic acid is degraded in plant cells to D-*myo*-inositol 1,2,4,5,6-pentakisphosphate and orthophosphate through the action of phytase. Manipulation of this enzyme activity could lead to a reduction of phytic acid levels in seeds and an increase in inositol trisphosphate and free phosphate, thus making phosphorus more metabolically available to

animals that are fed the seed. Another method to lower phytic acid levels is by inhibiting the activity of myo-inositol-1(or 4)-monophosphatase, which catalyzes the reaction:

myo-inositol 1-phosphate + H<sub>2</sub>O = myo-inositol + orthophosphate. Manipulation of the activity of this enzyme in developing seeds could decrease phytic acid levels in seeds and

increase levels of free phosphate. Lastly, phytic acid levels could also be reduced by inhibiting the activity of inositol trisphosphate kinase. This enzyme catalyzes the reaction:

ATP + 1D-myo-inositol 1,3,4-trisphosphate = ADP + 1D-myo-inositol

1,3,4,6-tetrakisphosphate. This reaction is one of the final steps leading to the formation of Myo-Inositol 1,2,3,4,5,6-hexaphosphate (phytic acid). Reduction in the activity of the

enzyme in developing seeds would interrupt phytic acid synthesis leaving the phosphate as the more metabolically available inositol trisphosphate and free phosphate.

In the United States, corn accounts for about 80% of the grain fed to all classes of livestock, including poultry, and is usually ground before feeding (Corn: Chemistry and Technology, 1987, American Association of Cereal Chemists, Inc., Edited by Stanley A. Watson and Paul E. Ramstad). A meal with decreased amounts of phytic acid and increased amounts of available phosphate would lead to improved feed efficiency in corn-containing rations, making available certain minerals especially zinc, magnesium, iron and calcium. Indeed, enzymatic treatment of soybean meal-containing rations to partially hydrolyze the phosphate groups from phytic acid improves both phosphate availability and the availability of other limiting nutrients. Also, in the wet milling of corn, phytate in the steepwater tends to precipitate, causing problems in handling, storing and transportation of the steep liquor. (Pen et al. (1993) *Biotechnology* 11:811-814). In light of these factors, it is apparent that corn plants with heritable, substantially reduced levels of phytic acid and increased levels of free phosphorous in their seeds would be desirable. Accordingly, the availability of nucleic acid sequences encoding all or a portion of these enzymes would facilitate studies to better understand carbohydrate metabolism and function in plants, provide genetic tools for the manipulation of these biosynthetic pathways, and provide a means to control carbohydrate transport and distribution in plant cells.

#### SUMMARY OF THE INVENTION

The instant invention relates to isolated nucleic acid fragments encoding phytic acid biosynthetic enzymes. Specifically, this invention concerns an isolated nucleic acid fragment encoding a myo-inositol-1 (or 4)-monophosphatase or a plant homolog of the *Synechocystis* sp. extragenic suppressor protein, a protein in the inositol monophosphatase family of proteins (Keneko, T., et al., (1996) *DNA Res.* 3(3):109-136). In addition, this invention relates to a nucleic acid fragment that is complementary to the nucleic acid fragment encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein.



An additional embodiment of the instant invention pertains to a polypeptide encoding all or a substantial portion of a phytic acid biosynthetic enzyme selected from the group consisting of myo-inositol-1 (or 4)-monophosphatase and extragenic suppressor proteins.

In another embodiment, the instant invention relates to a chimeric gene encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein, or to a chimeric gene that comprises a nucleic acid fragment that is complementary to a nucleic acid fragment encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein, operably linked to suitable regulatory sequences, wherein expression of the chimeric gene results in production of levels of the encoded protein in a transformed host cell that is altered (i.e., increased or decreased) from the level produced in an untransformed host cell.

In a further embodiment, the instant invention concerns a transformed host cell comprising in its genome a chimeric gene encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein, operably linked to suitable regulatory sequences. Expression of the chimeric gene results in production of altered levels of the encoded protein in the transformed host cell. The transformed host cell can be of eukaryotic or prokaryotic origin, and include cells derived from higher plants and microorganisms. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

An additional embodiment of the instant invention concerns a method of altering the level of expression of a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein in a transformed host cell comprising: a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein; and b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein in the transformed host cell.

An additional embodiment of the instant invention concerns a method for obtaining a nucleic acid fragment encoding all or a substantial portion of an amino acid sequence encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 presents an alignment of the amino acid sequence set forth in SEQ ID NOs:2, 4, 6 and 8 with the *Lycopersicon esculentum* IMP amino acid sequences (SEQ ID NO:21 and 22). Alignments were performed using the Clustal algorithm.

Figure 2 presents an alignment of the amino acid sequence set forth in SEQ ID NOs:10, 12, 14, 16, 18 and 20 with the *Synechocystis sp.* extragenic suppressor protein

amino acid sequences (SEQ ID NO:23 and 24). Alignments were performed using the Clustal algorithm.

The following sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

SEQ ID NO:1 is the nucleotide sequence comprising a portion of the cDNA insert in clone rl0n.pk127.f22 encoding a portion of a rice myo-inositol-1 (or 4)-monophosphatase.

SEQ ID NO:2 is the deduced amino acid sequence of a portion of a myo-inositol-1 (or 4)-monophosphatase derived from the nucleotide sequence of SEQ ID NO:1.

SEQ ID NO:3 is the nucleotide sequence comprising a portion of the cDNA insert in clone sfl1.pk0034.a12(5') encoding a portion of a soybean myo-inositol-1 (or 4)-monophosphatase.

SEQ ID NO:4 is the deduced amino acid sequence of a portion of a myo-inositol-1 (or 4)-monophosphatase derived from the nucleotide sequence of SEQ ID NO:3.

SEQ ID NO:5 is the nucleotide sequence comprising a portion of the cDNA insert in clone sfl1.pk0034.a12(3') encoding a portion of a soybean myo-inositol-1 (or 4)-monophosphatase.

SEQ ID NO:6 is the deduced amino acid sequence of a portion of a myo-inositol-1 (or 4)-monophosphatase derived from the nucleotide sequence of SEQ ID NO:5.

SEQ ID NO:7 is the nucleotide sequence comprising a the entire cDNA insert in clone wlmk1.pk0020.a9 encoding a wheat myo-inositol-1 (or 4)-monophosphatase.

SEQ ID NO:8 is the deduced amino acid sequence of a myo-inositol-1 (or 4)-monophosphatase derived from the nucleotide sequence of SEQ ID NO:7.

SEQ ID NO:9 is the nucleotide sequence comprising a portion of the cDNA insert in clone bsh1.pk0007.g11 encoding a portion of a barley extragenic suppressor protein.

SEQ ID NO:10 is the deduced amino acid sequence of a portion of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:9.

SEQ ID NO:11 is the nucleotide sequence comprising a portion of the cDNA insert in clone cco1n.pk066.p15 encoding a portion of a corn extragenic suppressor protein.

SEQ ID NO:12 is the deduced amino acid sequence of a portion of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:11.

SEQ ID NO:13 is the nucleotide sequence comprising the entire cDNA insert in clone cdt2c.pk003.b20 encoding a corn extragenic suppressor protein.

SEQ ID NO:14 is the deduced amino acid sequence of a portion of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:13.

SEQ ID NO:15 is the nucleotide sequence comprising a portion of the cDNA insert in clone rl0n.pk0062.c6 encoding a portion of a rice extragenic suppressor protein.

SEQ ID NO:16 is the deduced amino acid sequence of a portion of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:15.

SEQ ID NO:17 is the nucleotide sequence comprising a contig assembled from portions of the cDNA inserts in clones sl2.pk122.p24, src3c.pk013.g15 and sfl1n.pk003.g19 encoding a soybean extragenic suppressor protein.

SEQ ID NO:18 is the deduced amino acid sequence of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:17.

SEQ ID NO:19 is the nucleotide sequence comprising a portion of the cDNA insert in clone wlm0.pk0010.f6 encoding a portion of a wheat extragenic suppressor protein.

SEQ ID NO:20 is the deduced amino acid sequence of a portion of an extragenic suppressor protein derived from the nucleotide sequence of SEQ ID NO:19.

SEQ ID NO:21 is the amino acid sequence of myo-inositol-1 (or 4)-monophosphatase from *Lycopersicon esculentum* (NCBI Identification No. gi 1709203).

SEQ ID NO:22 is the amino acid sequence of myo-inositol-1 (or 4)-monophosphatase from *Lycopersicon esculentum* (NCBI Identification No. gi 1709205).

SEQ ID NO:23 is the amino acid sequence of extragenic suppressor protein from *Synechocystis sp.* (NCBI Identification No. gi 3915048).

SEQ ID NO:24 is the amino acid sequence of extragenic suppressor protein from *Synechocystis sp.* (NCBI Identification No. gi 1652942).

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Research* 13:3021-3030 (1985) and in the *Biochemical Journal* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. As used herein, an “isolated nucleic acid fragment” is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA. As used herein, “contig” refers to an assemblage of overlapping nucleic acid sequences to form one contiguous nucleotide sequence. For example, several DNA sequences can be compared and aligned to identify common or overlapping regions. The individual sequences can then be assembled into a single contiguous nucleotide sequence.

As used herein, “substantially similar” refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence.

“Substantially similar” also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by antisense or co-suppression technology. “Substantially

similar” also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate alteration of gene expression by antisense or co-suppression technology or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary sequences.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a gene which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded protein, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C), with the nucleic acid fragments disclosed herein.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent similarity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Preferred are those nucleic acid fragments whose nucleotide sequences encode amino acid sequences that are 80% similar to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are 90% similar to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are 95% similar to the amino acid sequences reported herein. Sequence alignments and percent similarity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins, D. G. and Sharp, P. M. (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10), (hereafter Clustal algorithm). Default parameters for pairwise alignments

using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A “substantial portion” of an amino acid or nucleotide sequence comprises enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to afford putative identification of that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a “substantial portion” of a nucleotide sequence comprises enough of the sequence to afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches partial or complete amino acid and nucleotide sequences encoding one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

“Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment that encodes all or a substantial portion of the amino acid sequence encoding the myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins as set forth in SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18 and 20. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments which are then enzymatically assembled to construct the entire gene. “Chemically synthesized”, as related to a sequence

of DNA, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of DNA may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as

“constitutive promoters”. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg, (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

The “translation leader sequence” refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G. D. (1995) *Molecular Biotechnology* 3:225).

The “3' non-coding sequences” refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., (1989) *Plant Cell* 1:671-680.

“RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into protein by the cell. “cDNA” refers to a double-stranded DNA that is complementary to and derived from mRNA. “Sense” RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. “Antisense RNA” refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. “Functional RNA” refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

“Antisense inhibition” refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. “Overexpression” refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. “Co-suppression” refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

“Altered levels” refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

“Mature” protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed.

“Precursor” protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A “chloroplast transit peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. “Chloroplast transit sequence” refers to a nucleotide sequence that encodes a chloroplast transit peptide. A “signal peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels, J. J., (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E. F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).



Nucleic acid fragments encoding at least a portion of several phytic acid biosynthetic enzymes have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. Table 1 lists the proteins that are described herein, and the designation of the cDNA clones that comprise the nucleic acid fragments encoding these proteins.

TABLE 1  
Phytic Acid Biosynthetic Enzymes

Enzyme	Clone	Plant
Myo-inositol-1 (or 4)-monophosphatase 1	rl0n.pk127.f22	Rice
	sfl1.pk0034.a12(5')	Soybean
	sfl1.pk0034.a12(3'')	Soybean
	wlmk1.pk0020.a9	wheat
Extragenic suppressor protein	bsh1.pk0007.g11	Barley
	cco1n.pk066.p15	Corn
	cdt2c.pk003.b20	Corn
	rl0n.pk0062.c6	Rice
	sl2.pk122.p24	Soybean
	src3c.pk013.g15	Soybean
	sfl1n.pk003.g19	Soybean
	wlm0.pk0010.f6	Wheat

The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In

addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

5 In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes  
10 advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al., (1988) *PNAS USA* 85:8998) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant  
15 sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al., (1989) *PNAS USA* 86:5673; Loh et al., (1989) *Science* 243:217). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman, M. A. and Martin, G. R., (1989) *Techniques* 1:165).

20 Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity  
25 for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner, R. A. (1984) *Adv. Immunol.* 36:1; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed myo-inositol-1 (or 4)-monophosphatase or extragenic  
30 suppressor proteins are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of phytic acid biosynthesis in those cells.

Overexpression of the myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins of the instant invention may be accomplished by first constructing a  
35 chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding

transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., (1985) *EMBO J.* 4:2411-2418; De Almeida et al., (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant phytic acid biosynthetic enzymes to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding sequence to encode myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein with appropriate intracellular targeting sequences such as transit sequences (Keegstra, K. (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels, J. J., (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel, N. (1992) *Plant Phys.* 100:1627-1632) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant phytic acid biosynthetic enzymes can be constructed by linking a gene or gene fragment encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

The instant myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting myo-inositol-1 (or

4)-monophosphatase or extragenic suppressor proteins *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded phytic acid biosynthetic enzymes. An example of a vector for high level expression of the instant myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor proteins in a bacterial host is provided (Example 7).

All or a substantial portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al., (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein, D. et al., (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in R. Bernatzky, R. and Tanksley, S. D. (1986) *Plant Mol. Biol. Reporter* 4(1):37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; *see* Hoheisel, J. D., et al., In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask,

B. J. (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan, M. et al. (1995) *Genome Research* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

5 A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian, H. H. (1989) *J. Lab. Clin. Med.* 114(2):95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield, V. C. et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren, U. et al. (1988) *Science* 241:1077-1080),  
10 nucleotide extension reactions (Sokolov, B. P. (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter, M. A. et al. (1997) *Nature Genetics* 7:22-28) and Happy Mapping (Dear, P. H. and Cook, P. R. (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is  
15 well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones  
20 either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer, (1989) *Proc. Natl. Acad. Sci USA* 86:9402; Koes et al., (1995) *Proc. Natl. Acad. Sci USA* 92:8149; Bensen et al., (1995) *Plant Cell* 7:75). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may  
25 be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the myo-inositol-1 (or  
30 4)-monophosphatase or extragenic suppressor protein. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the  
35 endogenous gene encoding a myo-inositol-1 (or 4)-monophosphatase or extragenic suppressor protein can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the gene product.

## EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

### EXAMPLE 1

#### Composition of cDNA Libraries: Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various barley, corn, rice, soybean and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Barley, Corn, Rice, Soybean and Wheat

Library	Tissue	Clone
bsh1	Barley sheath, developing seedling	bsh1.pk0007.g11
cco1n	Corn (Zea mays L.) cob of 67 day old plants grown in green house*	cco1n.pk066.p15(3')
cdt2c	Corn (Zea mays L.) developing tassel	cdt2c.pk003.b20
rl0n	Rice (Oryza sativa L.) 15 day leaf*	rl0n.pk0062.c6 rl0n.pk127.f22
sfl1	Soybean (Glycine max L.) immature flower	sfl1.pk0034.a12(5') sfl1.pk0034.a12(3'')
sfl1n	Soybean (Glycine max L.) immature flower*	sfl1n.pk003.g19
sl2	Soybean (Glycine max L.) two week old developing seedlings treated with 2.5 ppm chlorimuron	sl2.pk122.p24
src3c	Soybean (Glycine max L., Bell) 8 day old root inoculated with eggs of cyst nematode Heterodera glycines (Race 14) for 4 days.	src3c.pk013.g15
wlm0	Wheat (Triticum aestivum L.) seedlings 0 hr after inoculation with Erysiphe graminis f. sp tritici	wlm0.pk0010.f6
wlmk1	Wheat (Triticum aestivum L.) seedlings 1 hr after inoculation with Erysiphe graminis f. sp tritici and treatment with fungicide**	wlmk1.pk0020.a9

\*These libraries were normalized essentially as described in U.S. Patent No. 5,482,845

\*\*Application of 6-iodo-2-propoxy-3-propyl-4(3H)-quinazolinone; synthesis and methods of using this compound are described in USSN 08/545,827, incorporated herein by reference.

cDNA libraries were prepared in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). Conversion of the

Uni-ZAP™ XR libraries into plasmid libraries was accomplished according to the protocol provided by Stratagene. Upon conversion, cDNA inserts were contained in the plasmid vector pBluescript. cDNA inserts from randomly picked bacterial colonies containing recombinant pBluescript plasmids were amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences or plasmid DNA was prepared from cultured bacterial cells. Amplified insert DNAs or plasmid DNAs were sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or “ESTs”; see Adams, M. D. et al., (1991) *Science* 252:1651). The resulting ESTs were analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

## EXAMPLE 2

### Identification of cDNA Clones

ESTs encoding phytic acid biosynthetic enzymes were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST “nr” database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the “nr” database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the “nr” database using the BLASTX algorithm (Gish, W. and States, D. J. (1993) *Nature Genetics* 3:266-272 and Altschul, Stephen F., et al. (1997) *Nucleic Acids Res.* 25:3389-3402) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as “pLog” values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST “hit” represent homologous proteins.

## EXAMPLE 3

### Characterization of cDNA Clones Encoding Myo-Inositol-1 (or 4)-Monophosphatase Homologs

The BLASTX search using the EST sequences from clones rl0n.pk127.f22 and sfl1.pk0034.a12(3') revealed similarity of the proteins encoded by the cDNAs to myo-inositol-1 (or 4)-monophosphatase 1 from *Lycopersicon esculentum*. (NCBI Identification No. gi 1709203). The BLASTX search using the EST sequences from clones sfl1.pk0034.a12(5') and wlmk1.pk0020.a9 revealed similarity of the proteins encoded by the cDNAs to myo-inositol-1 (or 4)-monophosphatase 3 from *Lycopersicon esculentum*. (NCBI Identification No. gi 1709205).

The BLAST results for each of these ESTs are shown in Table 3:

**TABLE 3**

BLAST Results for Clones Encoding Polypeptides Homologous  
to *Lycopersicon esculentum* Myo-Inositol-1 (or 4)-Monophosphatase Proteins

Clone	BLAST pLog Score
rl0n.pk127.f22	54.40
sfl1.pk0034.a12(5')	89.00
sfl1.pk0034.a12(3')	23.70
wlmk1.pk0020.a9	130.00

The sequence of a portion of the cDNA insert from clone rl0n.pk127.f22 is shown in SEQ ID NO:1; the deduced amino acid sequence of this cDNA, which represents 42% of the of the protein (N-terminal region), is shown in SEQ ID NO:2. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:2 and the *Lycopersicon esculentum* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:2 is 77% similar to the *Lycopersicon esculentum* IMP-1 protein.

The sequence of a portion of the cDNA insert from clone sfl1.pk0034.a12(5') is shown in SEQ ID NO:3; the deduced amino acid sequence of this cDNA, which represents 63% of the of the protein (N-terminal region), is shown in SEQ ID NO:4. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:4 and the *Lycopersicon esculentum* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:4 is 74% similar to the *Lycopersicon esculentum* IMP-3 protein.

The sequence of a portion of the cDNA insert from clone sfl1.pk0034.a12(3') is shown in SEQ ID NO:5; the deduced amino acid sequence of this cDNA, which represents 27% of the of the protein (C-terminal region), is shown in SEQ ID NO:6. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:6 and the *Lycopersicon esculentum* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:6 is 58% similar to the *Lycopersicon esculentum* IMP-1 protein.

The sequence of the entire cDNA insert from clone wlmk1.pk0020.a9 is shown in SEQ ID NO:7; the deduced amino acid sequence of this cDNA, which represents 100% of the of the protein, is shown in SEQ ID NO:8. The amino acid sequence set forth in SEQ ID NO:8 was evaluated by BLASTP, yielding a pLog value of 113.00 versus the *Lycopersicon esculentum* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:8 and the *Lycopersicon esculentum* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO: is 69% similar to the *Lycopersicon esculentum* IMP-3 protein.



Figure 1 presents an alignment of the amino acid sequence set forth in SEQ ID NOs:2, 4, 6 and 8 with the *Lycopersicon esculentum* IMP amino acid sequences, SEQ ID NO:21 and 22. Alignments were performed using the Clustal algorithm.

These sequences represent the first rice, soybean and wheat sequences encoding myo-inositol-1 (or 4)-monophosphatase proteins.

#### EXAMPLE 4

##### Characterization of cDNA Clones Encoding Extragenic Suppressor Proteins

The BLASTX search using the EST sequences from clones bsh1.pk0007.g11, cco1n.pk066.p15 and rl0n.pk0062.c6 revealed similarity of the proteins encoded by the cDNAs to extragenic suppressor protein from *Synechocystis sp.* (NCBI Identification No. gi 3915048). The BLASTX search using the EST sequences from clones cdt2c.pk003.b20, sl2.pk122.p24, src3c.pk013.g15, sfl1n.pk003.g19 and wlm0.pk0010.f6 revealed similarity of the proteins encoded by the cDNAs to extragenic suppressor protein from *Synechocystis sp.* (NCBI Identification No. gi 1652942).

In the process of comparing the ESTs it was found that soybean clones sl2.pk122.p24, src3c.pk013.g15 and sfl1n.pk003.g19 had overlapping regions of homology. Using this homology it was possible to align the ESTs and assemble a contig encoding a unique soybean extragenic suppressor protein.

The BLAST results for each of the ESTs and the soybean contig are shown in Table 4:

TABLE 4

BLAST Results for Clones Encoding Polypeptides Homologous to *Synechocystis sp* Extragenic Suppressor Protein

Clone	BLAST pLog Score
bsh1.pk0007.g11	46.10
cco1n.pk066.p15	21.70
cdt2c.pk003.b20	30.40
rl0n.pk0062.c6	22.30
Contig composed of clones:	24.70
sl2.pk122.p24	
src3c.pk013.g15	
sfl1n.pk003.g19	
wlm0.pk0010.f6	29.40

The sequence of a portion of the cDNA insert from clone bsh1.pk0007.g11 is shown in SEQ ID NO:9; the deduced amino acid sequence of this cDNA, which represents 74% of the of the protein (C-terminal region), is shown in SEQ ID NO:10. The amino acid sequence set forth in SEQ ID NO:10 was evaluated by BLASTP, yielding a pLog value of 40.30 versus the *Synechocystis sp.* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:10 and the *Synechocystis sp.* sequence (using the Clustal

algorithm) revealed that the protein encoded by SEQ ID NO:10 is 34% similar to the *Synechocystis sp.* extragenic suppressor protein.

The sequence of a portion of the cDNA insert from clone ccoln.pk066.p15 is shown in SEQ ID NO:11; the deduced amino acid sequence of this cDNA, which represents 40% of the of the protein (C-terminal region), is shown in SEQ ID NO:12. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:12 and the *Synechocystis sp.* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:12 is 34% similar to the *Synechocystis sp.* extragenic suppressor protein.

The sequence of the entire cDNA insert from clone cdt2c.pk003.b20 is shown in SEQ ID NO:13; the deduced amino acid sequence of this cDNA, which represents 100% of the of the protein, is shown in SEQ ID NO:14. The amino acid sequence set forth in SEQ ID NO:14 was evaluated by BLASTP, yielding a pLog value of 34.70 versus the *Synechocystis sp.* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:14 and the *Synechocystis sp.* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:14 is 28% similar to the *Synechocystis sp.* extragenic suppressor protein.

The sequence of a portion of the cDNA insert from clone rl0n.pk0062.c6 is shown in SEQ ID NO:15; the deduced amino acid sequence of this cDNA, which represents 42% of the of the protein (C-terminal region), is shown in SEQ ID NO:16. The amino acid sequence set forth in SEQ ID NO:16 was evaluated by BLASTP, yielding a pLog value of 18.52 versus the *Synechocystis sp.* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:16 and the *Synechocystis sp.* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:16 is 33% similar to the *Synechocystis sp.* extragenic suppressor protein.

The sequence of the soybean contig composed of clones sl2.pk122.p24, src3c.pk013.g15 and sfl1n.pk003.g19 is shown in SEQ ID NO:17; the deduced amino acid sequence of this cDNA, which represents 100% of the of the protein, is shown in SEQ ID NO:18. The amino acid sequence set forth in SEQ ID NO:18 was evaluated by BLASTP, yielding a pLog value of 32.00 versus the *Synechocystis sp.* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:18 and the *Synechocystis sp.* sequence (using the Clustal algorithm) revealed that the protein encoded by SEQ ID NO:18 is 26% similar to the *Synechocystis sp.* extragenic suppressor protein.

The sequence of a portion of the cDNA insert from clone wlm0.pk0010.f6 is shown in SEQ ID NO:19; the deduced amino acid sequence of this cDNA, which represents 96% of the of the protein, is shown in SEQ ID NO:20. The amino acid sequence set forth in SEQ ID NO:20 was evaluated by BLASTP, yielding a pLog value of 35.22 versus the *Synechocystis sp.* sequence. A calculation of the percent similarity of the amino acid sequence set forth in SEQ ID NO:20 and the *Synechocystis sp.* sequence (using the Clustal algorithm) revealed

that the protein encoded by SEQ ID NO:20 is 25% similar to the *Synechocystis sp.* extragenic suppressor protein.

Figure 2 presents an alignment of the amino acid sequence set forth in SEQ ID NOs:10, 12, 14, 16, 18 and 20 with the *Synechocystis sp.* extragenic suppressor protein amino acid sequences, SEQ ID NO:23 and 24. Alignments were performed using the Clustal algorithm.

These sequences represent the first plant sequences encoding extragenic suppressor proteins.

#### EXAMPLE 5

##### Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding phytic acid biosynthetic enzyme in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb SalI-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-SalI fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding a phytic acid biosynthetic enzyme, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al., (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable

embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al., (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1  $\mu\text{m}$  in diameter) are coated with DNA using the following technique. Ten  $\mu\text{g}$  of plasmid DNAs are added to 50  $\mu\text{L}$  of a suspension of gold particles (60 mg per mL). Calcium chloride (50  $\mu\text{L}$  of a 2.5 M solution) and spermidine free base (20  $\mu\text{L}$  of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200  $\mu\text{L}$  of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30  $\mu\text{L}$  of ethanol. An aliquot (5  $\mu\text{L}$ ) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-

supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al., (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 6

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant phytic acid biosynthetic enzymes in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising a sequence encoding the phytic acid biosynthetic enzyme. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Kline et al. (1987) *Nature* (London) 327:70, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al.(1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the phytic acid biosynthetic enzyme and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50  $\mu$ L of a 60 mg/mL 1  $\mu$ m gold particle suspension is added (in order): 5  $\mu$ L DNA (1  $\mu$ g/ $\mu$ L), 20  $\mu$ L spermidine (0.1 M), and 50  $\mu$ L  $\text{CaCl}_2$  (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400  $\mu$ L 70% ethanol and resuspended in 40  $\mu$ L of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five  $\mu$ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 7

##### Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant phytic acid biosynthetic enzymes can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing

EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the phytic acid biosynthetic enzyme are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

CLAIMS

What is claimed is:

1. An isolated nucleic acid fragment encoding all or a substantial portion of a myo-inositol-1 (or 4)-monophosphatase comprising a member selected from the group consisting of:

- (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 6 and 8;
- (b) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 6 and 8; and
- (c) an isolated nucleic acid fragment that is complementary to (a) or (b).

2. The isolated nucleic acid fragment of Claim 1 wherein the nucleotide sequence of the fragment comprises all or a portion of the sequence set forth in a member selected from the group consisting of SEQ ID NO:1, 3, 5 and 7.

3. A chimeric gene comprising the nucleic acid fragment of Claim 1 operably linked to suitable regulatory sequences.

4. A transformed host cell comprising the chimeric gene of Claim 3.

5. A myo-inositol-1 (or 4)-monophosphatase polypeptide comprising all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 6 and 8.

6. An isolated nucleic acid fragment encoding all or a substantial portion of an extragenic suppressor protein comprising a member selected from the group consisting of:

- (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18 and 20;
- (b) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18 and 20; and
- (c) an isolated nucleic acid fragment that is complementary to (a) or (b).

7. The isolated nucleic acid fragment of Claim 6 wherein the nucleotide sequence of the fragment comprises all or a portion of the sequence set forth in a member selected from the group consisting of SEQ ID NO:9, 11, 13, 15, 17 and 19.

8. A chimeric gene comprising the nucleic acid fragment of Claim 6 operably linked to suitable regulatory sequences.

9. A transformed host cell comprising the chimeric gene of Claim 8.



10. A extragenic suppressor protein polypeptide comprising all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:10, 12, 14, 16, 18 and 20.

11. A method of altering the level of expression of a phytic acid biosynthetic enzyme in a host cell comprising:

- (a) transforming a host cell with the chimeric gene of any of Claims 3 and 8; and
- (b) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene

wherein expression of the chimeric gene results in production of altered levels of a phytic acid biosynthetic enzyme in the transformed host cell.

12. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a phytic acid biosynthetic enzyme comprising:

- (a) probing a cDNA or genomic library with the nucleic acid fragment of any of Claims 1 and 6 ;
- (b) identifying a DNA clone that hybridizes with the nucleic acid fragment of any of Claims 1 and 6;
- (c) isolating the DNA clone identified in step (b); and
- (d) sequencing the cDNA or genomic fragment that comprises the clone isolated in step (c)

wherein the sequenced nucleic acid fragment encodes all or a substantial portion of the amino acid sequence encoding a phytic acid biosynthetic enzyme.

13. A method of obtaining a nucleic acid fragment encoding a substantial portion of an amino acid sequence encoding a phytic acid biosynthetic enzyme comprising:

- (a) synthesizing an oligonucleotide primer corresponding to a portion of the sequence set forth in any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17 and 19; and
- (b) amplifying a cDNA insert present in a cloning vector using the oligonucleotide primer of step (a) and a primer representing sequences of the cloning vector

wherein the amplified nucleic acid fragment encodes a substantial portion of an amino acid sequence encoding a phytic acid biosynthetic enzyme.

14. The product of the method of Claim 12.

15. The product of the method of Claim 13.

TITLE

## PHYTIC ACID BIOSYNTHETIC ENZYMES

ABSTRACT OF THE DISCLOSURE

This invention relates to an isolated nucleic acid fragment encoding a phytic acid  
5 biosynthetic enzyme. The invention also relates to the construction of a chimeric gene  
encoding all or a portion of the phytic acid biosynthetic enzyme, in sense or antisense  
orientation, wherein expression of the chimeric gene results in production of altered levels of  
the phytic acid biosynthetic enzyme in a transformed host cell.

10

15

20

25

30

35

TMR/dmm

Figure 1

```

1      60
SEQ ID NO:21 (gi 1709203) MARNGLSEELFLGVAADAAKRAGEIIRKGFHETKHVVHKQGVDLVTETDKACEDLIENHLK
SEQ ID NO:22 (gi 1709205) MAQNGSVEQFLDVAVEAAKAGEIIRREGFYKTKHVEHKGMVDLVETDKACEDFIENHLK
SEQ ID NO:2  MAE-----EQFLAVAVDAAKNAGEIIRKGFYQTKNVEHKQGVDLVTETDKACEDLIENHLR
SEQ ID NO:4  MVDNDSLSEFLASAVDAQAAGEIIRKGFYQTKNVEHKQGVDLVTETDKACEELIENHLK
SEQ ID NO:6  -----
SEQ ID NO:8  MAE-----EQFLAAAVGAAKSAGEIIRKSFYLSKKVEHKQGVDLVTETDKACEDLIENHLR

61      120
SEQ ID NO:21 (gi 1709203) QHFPCHKFIGEETSAAT-GDFDLTDEPTWIVDFVDTTNFVHGFPSCVCSIGLTIGKIPT
SEQ ID NO:22 (gi 1709205) QRFPSHKFIGEETTAA-CGNFELTDEPTWIVDPLDGTTFVHGFPFVCVCSIGLTIEKKPT
SEQ ID NO:2  KHPDHKFIGEETSAGLADLTDDPTWIVDPLDGTTFVHGFPFVCVCSIGLTVGK---
SEQ ID NO:4  QLYPTHKFIGEETTAA-YGTTELTDPTWIVDPLDGTTFVHGFPFVCVCSIGLTIGKTPT
SEQ ID NO:6  -----
SEQ ID NO:8  MLYPDHKFIGEETSAALGSTDDLTYDPTWIVDPLDGTTFVHGFPFVCVCSIGLTIGKIPT

121      180
SEQ ID NO:21 (gi 1709203) VGVVYDPIIDELFTGINGKGAYLNGKPIKVSSQSELVKSLLGTEVGTTRDNLTVETTRR
SEQ ID NO:22 (gi 1709205) VGVVYNPIIDELFTGIDGKGAFLNGKPIKVSSQSELVKALLATEAGTNRDKLVVDATTGR
SEQ ID NO:2  -----
SEQ ID NO:4  IGVVYNPIINELFTGIHGKGAFLNGNPIKVSSQTELISSLLATEAGTKR-----
SEQ ID NO:6  -----
SEQ ID NO:8  VGVVYNPIMNELFTAVRGKGAFLNGSPIKTSQNELVKALMVTEVGTKRDKSTLDDTTNR

181      240
SEQ ID NO:21 (gi 1709203) INNLLFKVRSRLRMCGSCALDLCWVACGRLELFYLICYGGPWDVAGGAVIVKEAGGVLFDP
SEQ ID NO:22 (gi 1709205) INSLLFKVRSRLRMCGSCALNLCGVACGRDLDFYELEFGGPPWDVAGGAVIVKEAGGFVDP
SEQ ID NO:2  -----
SEQ ID NO:4  -----VLRGGAGLS-----
SEQ ID NO:6  -----IACGRLDVFFELGFGGPPWDVAGGAVIVREAGGVVDP
SEQ ID NO:8  INKLLFKIRSIRMCGSLALNMCGVACGRDLDCYEICGFGGPPWDVAAGALILKEAGGFVDP

241      277
SEQ ID NO:21 (gi 1709203) SGSEFDITSQRVAATNPHLKEAFVEA---LQLSEYVS
SEQ ID NO:22 (gi 1709205) SGSEFDLTARRVAATNAHLKDAFIKA---LNE-----
SEQ ID NO:2  -----I-----
SEQ ID NO:4  -----T-----
SEQ ID NO:6  SGADFAITSQRVAVSNPFKKDELIVETRRKMGWEIYN.
SEQ ID NO:8  SGDEFDLMAQRMAGSNGHLKDQFIKA---LGDAS.---

```

Figure 2

SEQ ID NO:23	(gi 3915048)	1	M-----TSAQKPVF-----SPSDLQT-----WL-----	60
SEQ ID NO:24	(gi 1652942)		ML-----PEVEQLF-----	
SEQ ID NO:10			-----	
SEQ ID NO:12			-----	
SEQ ID NO:14			MLSSSSSTHSDTSPFGLASANPNRSLRLRLRAASPVS SAVLSASGRQP-----MSTV	
SEQ ID NO:16			-----	
SEQ ID NO:18			MFSQCH-----FLSHSPIPNTT--FRLRAMAPHST-----	
SEQ ID NO:20			-----HETKPSLP-----YHLRSPSLLATFSSSAAGRACGIAGRWMGSV	
SEQ ID NO:23	(gi 3915048)	61	-----EIA TEAVLAAGAEI--FSLWGKVQOIQEKGRAG	120
SEQ ID NO:24	(gi 1652942)		-----IAQQLAAVSGEILIQYFRRSHLQGGTKIDQVS	
SEQ ID NO:10			-----	
SEQ ID NO:12			-----	
SEQ ID NO:14			RASFAAGAAARRAAVGE--LATERLVEAQRADAAGEVLRKYFRQ-RVEIIDKEDHSP	
SEQ ID NO:16			-----	
SEQ ID NO:18			-----PLELNRF AEVGNKVADAAGEVIRKYFRK-NFDVIHKHDLSP	
SEQ ID NO:20			RAS-PSEAGGWAVAAAGKEGVDMERLVAVAQSAADAAGEVLRKYFRQ-RFEIIDKEDHSP	
SEQ ID NO:23	(gi 3915048)	121	DLVTEADRQAEAIILETIKRRCPDHAILAEESG-QLGQVDNPF CWAIDPLDGT TNFAHSY	180
SEQ ID NO:24	(gi 1652942)		AIVTQADEEAEQAMVDLIQAQFPQDGVIREEG--KNIAGKSGYTWVLDPIDGTSSSFVRGL	
SEQ ID NO:10			----HEDKLSSEVILEVVTKNFRDHLILGEEG-LIGDSLSEYLWCIDPLDGT TNFAHGY	
SEQ ID NO:12			-----	
SEQ ID NO:14			--VTIADREAEEMVSVILKSPPTTHAIFGEENGWRC AENSADFVWVLDPIDGT KSFITGK	
SEQ ID NO:16			----HE-----	
SEQ ID NO:18			--VTIADQSAEEAMVSIILDNFP SHAIYGEENGWRC EKNADYVWVLDPIDGT KSFITGK	
SEQ ID NO:20			--VTIADREAEEMVSVILKSPPTTHAVFGEENGWRC A EKSADYVWVLDPIDGT KSFITGK	

181 240  
 SEQ ID NO:23 (gi 3915048) PVSCVSIIGLLIQIDPTVGVVYNPFRQELFRAATSLGATLNR-----PPIQVSTTASLDK  
 SEQ ID NO:24 (gi 1652942) PIFATLIGLVDAMRPVLGIAHQPISGDRWQVGQEQSNVNGIP-LVNPYKASEINLTAA  
 SEQ ID NO:10 PSFSVIGVLYRGKPAATVVEFCGGPMCWSRTISASSGKAYCNGQKIHVSPTEKVEQ  
 SEQ ID NO:12 -----MCWTTRTIIFPFAGGAYYIGQRIHVSTQTDKVEQ  
 SEQ ID NO:14 PLFGTLIALLHNG-KPVIIGVIDQPIILRERWIGVDGKQTTLNGQE-I--SVRSCNL-LAQA  
 SEQ ID NO:16 -----LTKVEQ  
 SEQ ID NO:18 PVFGTLVALLQNG-TPILGIIDQPVLRERWIGIAGKRTSLNGQE-I--STRTCAD-LSQA  
 SEQ ID NO:20 PLFGTLIALLHNG-KPVMGIIDQPIILRERWVGVDGKKTTLNGQE-I--SVRPCNV-LEQA

241 300  
 SEQ ID NO:23 (gi 3915048) SLLVTG---FAYDRVKTLDNNYPEFCYLTHLTQGVRRSGSAAIDLIDVACGRLDGYWERG  
 SEQ ID NO:24 (gi 1652942) CIVSTPLMFTTPVQOKMADIYRQCQRTAFGGDCFNLYLSAASGWTAMPLVIVEA----D  
 SEQ ID NO:10 SLLVTG---FGYEHDDAWLTNINLFKEFTDVSRGVRRLGSAADMSHVGLGITEAYWEYR  
 SEQ ID NO:12 SLLVTGFGYEHDDAWTNMNLFEFTDISRGVRR--LGSAAADMSHIGLITE---AYWE  
 SEQ ID NO:14 YLYTSPHLFEADAEDA-FIRVRNKVPLYGCDYAYALLASGFVDI---VVES-----G  
 SEQ ID NO:16 SLLVTG---FGYEHDDAWTNINLFKEYTDISRGVRRLGSAADMSHVALGITEAYWEYR  
 SEQ ID NO:18 YLYTSPHLFNGDAEEA-FIRVRSKVKFQLYGDCYAYALLSSGFVDL---VVES-----G  
 SEQ ID NO:20 YLYTSPHLFEGDAEDA-FIRVRDKVKPLYGDCYAYALLASGFVDL---VVES-----G

301 360  
 SEQ ID NO:23 (gi 3915048) INPWDMAAGIVIVREAGGIVSAYDCSPLDLSTGRILATNGKIHQELSQAALATPQ-----  
 SEQ ID NO:24 (gi 1652942) LNFYDFCALIPILTGANYCFTDWQKEL-----TPESTEVVASPNPKLHSE  
 SEQ ID NO:10 LKPWMAAGVLIIVEEAGGVVTRMDGGEFTVDRSVLVSNVVDQLLERIRPATEDLKKK  
 SEQ ID NO:12 YRLKPWDVHAGVLIIVEEAGGVVTRMDGGEFTVDRSVLVSNGLVHGQV-----  
 SEQ ID NO:14 LKPYDFLSLVPVIEGAGGSITDWRGDKLH-----WPVTAESRPTSFNVVAAGDARVHKE  
 SEQ ID NO:16 LKPWMAAGVLIIVEEAGGVVTRMDGGEFTVDRSVLVSNVVDQLDRIGPATEDLKKK  
 SEQ ID NO:18 LKPYDFLALIPVIEGAGGVITDWKDKLF-----WEASPLSIATSFNVVAAGDKQIHQQ  
 SEQ ID NO:20 LKPYDFLSLVPVIEGAGGSITDWEKNKLH-----WPVSESRPTSFNVVAAGDSHVHGQ

361 381  
 SEQ ID NO:23 (gi 3915048) -----WF--QQYAAARAQKI  
 SEQ ID NO:24 (gi 1652942) ILAFL---Q-----  
 SEQ ID NO:10 GIDFSLWFKPKDKYPT---DF.  
 SEQ ID NO:12 -----CL  
 SEQ ID NO:14 ALDALRWR.-----  
 SEQ ID NO:16 GIDFSLWFKPKDKYPT---DF.  
 SEQ ID NO:18 ALDSLQWK.-----  
 SEQ ID NO:20 ALAALRWR.-----

**EXPRESS MAIL LABEL NO. EL073740935US**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN THE APPLICATION OF:

E. I. DUPONT DE NEMOURS AND COMPANY

CASE NO.: BB1165

APPLICATION NO.: UNKNOWN

GROUP ART UNIT: UNKNOWN

FILED: CONCURRENTLY HEREWITH

EXAMINER: UNKNOWN

FOR: **PHYTIC ACID BIOSYNTHETIC ENZYMES**

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

**DECLARATION IN ACCORDANCE WITH 37 CFR 1.821**

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively are the same.

Respectfully submitted,



THOMAS M. RIZZO  
ATTORNEY FOR APPLICANTS  
REGISTRATION NO. 41,272  
TELEPHONE: 302-892-7760  
FACSIMILE: 302-892-1026

Dated: October 11, 2000

# SEQUENCE LISTING

<110> Cahoon, Rebecca E.  
Hitz, William D.  
Thorpe, Catherine J.  
Tingey, Scott V.

<120> PHYTIC ACID BIOSYNTHETIC ENZYMES

<130> BB1165 US NA

<140>

<141>

<150> 60/082,960

<151> APRIL 24, 1998

<150> PCT/US99/08790

<151> APRIL 22, 1999

<160> 24

<170> Microsoft Office 97

<210> 1

<211> 462

<212> DNA

<213> Oryza sativa

<400> 1

```

cttacatgta agctcgtatt ttcttctcta cacaaccgaa aggtggagcg ttggcgaagg 60
accaaccaat ttcctctctc taatcgccgc ggcgggggat agattgggag tgagcgcgta 120
tggcggagga gcagttcctc gccgtcgcgg tggacgcgcg caagaacgcc ggcgagatca 180
tccgcaaggg cttctaccag accaagaacg tggagcacia gggccagggtg gatttggtga 240
cggagacgga caaggcctgc gaggacctca tcttcaacca cctccggaag cactaccgg 300
accacaagtt catcggcgag gagacgtccg cggggctcgg cgccaccgcg gacctaccg 360
acgacccgac ctggatcgtc gacccctcgc atggcaccac caatttcgtc catggcttcc 420
cttttgtttg cgtctcgatc ggtctcaccg tcgggaaaat tc 462

```

<210> 2

<211> 114

<212> PRT

<213> Oryza sativa

<400> 2

```

Met Ala Glu Glu Gln Phe Leu Ala Val Ala Val Asp Ala Ala Lys Asn
 1             5             10             15

```

```

Ala Gly Glu Ile Ile Arg Lys Gly Phe Tyr Gln Thr Lys Asn Val Glu
      20             25             30

```

```

His Lys Gly Gln Val Asp Leu Val Thr Glu Thr Asp Lys Ala Cys Glu
      35             40             45

```

```

Asp Leu Ile Phe Asn His Leu Arg Lys His Tyr Pro Asp His Lys Phe
      50             55             60

```

```

Ile Gly Glu Glu Thr Ser Ala Gly Leu Gly Ala Thr Ala Asp Leu Thr
      65             70             75             80

```

```

Asp Asp Pro Thr Trp Ile Val Asp Pro Leu Asp Gly Thr Thr Asn Phe
      85             90             95

```

```

Val His Gly Phe Pro Phe Val Cys Val Ser Ile Gly Leu Thr Val Gly
      100            105            110

```

Lys Ile  
114

<210> 3  
<211> 561  
<212> DNA  
<213> Glycine max

<220>  
<221> unsure  
<222> (529)..(530)

<220>  
<221> unsure  
<222> (543)

<220>  
<221> unsure  
<222> (546)

<220>  
<221> unsure  
<222> (552)

<220>  
<221> unsure  
<222> (556)

<400> 3  
gaagaaagca gagcctctac tacatcatca cattcacatt tcagtacctt ctctttctcc 60  
cagtctctca cacacaacaa ttgaagaaga aaatggttga caatgattcg ctctcggaat 120  
tcctcgcatc tgcggtcgac gcggctcaga aagctggcga gattattcga aaaggcttct 180  
accagaccaa aaatgtggaa cacaaaggac aggttgattt ggtcacagaa actgataaag 240  
catgtgaaga actcatatct aatcatctga aacagcttta tcccactcac aagttcattg 300  
gggaagagac cacagctgcc tatggcacta cagaacttac agatgaacc acatggatat 360  
tgatccctgg atggaactac taacttgtgc atgggttccc ttgtttgtg tccattggc 420  
tcacaattgg aaaaatctac aattggtgtt gtatacaatc aatataatga cttttctgga 480  
tcatggaaaa gtgccttttg atgggaatcc ataaatgtct cacaacgann atcagcctct 540  
ctncantgag gngganaaaa c 561

<210> 4  
<211> 168  
<212> PRT  
<213> Glycine max

<400> 4  
Met Val Asp Asn Asp Ser Leu Ser Glu Phe Leu Ala Ser Ala Val Asp  
1 5 10 15  
Ala Ala Gln Lys Ala Gly Glu Ile Ile Arg Lys Gly Phe Tyr Gln Thr  
20 25 30  
Lys Asn Val Glu His Lys Gly Gln Val Asp Leu Val Thr Glu Thr Asp  
35 40 45  
Lys Ala Cys Glu Glu Leu Ile Phe Asn His Leu Lys Gln Leu Tyr Pro  
50 55 60  
Thr His Lys Phe Ile Gly Glu Glu Thr Thr Ala Ala Tyr Gly Thr Thr  
65 70 75 80  
Glu Leu Thr Asp Glu Pro Thr Trp Ile Val Asp Pro Leu Asp Gly Thr  
85 90 95  
Thr Asn Phe Val His Gly Phe Pro Phe Val Cys Val Ser Ile Gly Leu  
100 105 110



Thr Ile Gly Lys Thr Pro Thr Ile Gly Val Val Tyr Asn Pro Ile Ile  
 115 120 125

Asn Glu Leu Phe Thr Gly Ile His Gly Lys Gly Ala Phe Leu Asn Gly  
 130 135 140

Asn Pro Ile Lys Val Ser Ser Gln Thr Glu Leu Ile Ser Ser Leu Leu  
 145 150 155 160

Ala Thr Glu Ala Gly Thr Lys Arg  
 165

<210> 5  
 <211> 667  
 <212> DNA  
 <213> Glycine max

<400> 5  
 gaattgcatg tgggaaggctg gatgtattct ttgaacttgg ctttggtggt ccttgggatg 60  
 tagcaggtgg tgctgtcatt gttagagaag ctggagggtg tgtatttgat ccgtccgggtg 120  
 cagattttgc aataacatct cagcgagtag cagtttcaaa ccctttctaa aaggatgaac 180  
 ttgtggaaac tcggcgcaaa atgggggtgg aaattttacaa ttaaccattg gcaagacctt 240  
 acaagatagc caacctttgt tagtccgtta acctttggcc caaagagttt tttagattcc 300  
 aagtttttacg tagaagttcc aggttaaaaaa ggtttttagaa ttttaacttc ctccggggggc 360  
 tcaagagaat ccataataaa tcaactttta tccctttaac caagggccaa gtccaacgaa 420  
 aaaaaactcc ctaaacaatgg gaagaagcac ctccacaggg cagcggttcc caaacctggt 480  
 cggaaggcc gtgggcattc gggaaaccgg taccaatcaa ggatcctccc ggaacccaaa 540  
 ggcaaggcaa accgcggcac gggcttgggc caaaccccg tgaaccgccg cccaccaacg 600  
 gggagttcaa agcccaaggg gggaaaaggg gactttggcg gtccaaaact ttcacaaccg 660  
 ggggccc 667

<210> 6  
 <211> 73  
 <212> PRT  
 <213> Glycine max

<400> 6  
 Ile Ala Cys Gly Arg Leu Asp Val Phe Phe Glu Leu Gly Phe Gly Gly  
 1 5 10 15

Pro Trp Asp Val Ala Gly Gly Ala Val Ile Val Arg Glu Ala Gly Gly  
 20 25 30

Val Val Phe Asp Pro Ser Gly Ala Asp Phe Ala Ile Thr Ser Gln Arg  
 35 40 45

Val Ala Val Ser Asn Pro Phe Xaa Lys Asp Glu Leu Val Glu Thr Arg  
 50 55 60

Arg Lys Met Gly Trp Glu Ile Tyr Asn  
 65 70

<210> 7  
 <211> 1003  
 <212> DNA  
 <213> Triticum aestivum

<400> 7  
 acgaggggaga ttccgaagcc atggcgagg agcagttcct ggccgcagct gtgggcccgcg 60  
 ccaagagcgc cggcgagatt atccgcaaga gcttttaoct aagcaagaaa gtggagcaca 120  
 agggccaggt ggatttggtg acggagacgg acaaggcatg cgaggatctc atcttcaacc 180  
 acctccgat gctctaccg gaccacaagt tcctcggcga ggagacgtct gcagccctcg 240  
 gctccaccga tgacctcacc tacgaccca cctggatagt cgacccctc gatggcacca 300  
 ccaacttcgt tcatggcttt ctttttgtgt gcgtctcgat tggcctcacc attgggaaga 360  
 tccccaccgt tggagttgtg tacaaccca tcatgaatga gcttttcaca gctgttcgtg 420

```

gaaaagggtgc ttttctcaat ggctctccaa ttaaaacatc gcctcaaaat gagttggtga 480
aggctcttat ggtgacagag gtagggacca aaagagacaa gtccactttg gatgatacaa 540
ccaacagaat taataagtta ctattcaaga ttagatctat acgtatgtgt ggctcttttg 600
ctctaaacat gtgtggagtt gcttgtggta ggctagattt gtgttatgag atcgggtttg 660
gtggcccctg ggatgtggct gctggagctt tgattctaaa ggaagctggg ggttttgttt 720
ttgatccgag cgggtgatgag tttgatctga tggcgcaaaag aatggcagga tcaaattggcc 780
acctcaagga tcagttcatc aaagcattgg gagatgcaag ctgaataact tatttctctt 840
ttcaagtaga atgaaagaat gtaagatggc cccaccaata agtaattgag ggctactttt 900
tgtgtagtgc tatatgcata ttttgcaaac gtggcggatg taatgacatt ggatatattg 960
ctcgttttat ttaccatgca aggtgtgatc aaaaaaaaaa aaa 1003

```

```

<210> 8
<211> 267
<212> PRT
<213> Triticum aestivum

```

```

<400> 8
Met Ala Glu Glu Gln Phe Leu Ala Ala Ala Val Gly Ala Ala Lys Ser
 1          5          10          15

Ala Gly Glu Ile Ile Arg Lys Ser Phe Tyr Leu Ser Lys Lys Val Glu
          20          25          30

His Lys Gly Gln Val Asp Leu Val Thr Glu Thr Asp Lys Ala Cys Glu
          35          40          45

Asp Leu Ile Phe Asn His Leu Arg Met Leu Tyr Pro Asp His Lys Phe
          50          55          60

Ile Gly Glu Glu Thr Ser Ala Ala Leu Gly Ser Thr Asp Asp Leu Thr
          65          70          75          80

Tyr Asp Pro Thr Trp Ile Val Asp Pro Leu Asp Gly Thr Thr Asn Phe
          85          90          95

Val His Gly Phe Pro Phe Val Cys Val Ser Ile Gly Leu Thr Ile Gly
          100          105          110

Lys Ile Pro Thr Val Gly Val Val Tyr Asn Pro Ile Met Asn Glu Leu
          115          120          125

Phe Thr Ala Val Arg Gly Lys Gly Ala Phe Leu Asn Gly Ser Pro Ile
          130          135          140

Lys Thr Ser Pro Gln Asn Glu Leu Val Lys Ala Leu Met Val Thr Glu
          145          150          155          160

Val Gly Thr Lys Arg Asp Lys Ser Thr Leu Asp Asp Thr Thr Asn Arg
          165          170          175

Ile Asn Lys Leu Leu Phe Lys Ile Arg Ser Ile Arg Met Cys Gly Ser
          180          185          190

Leu Ala Leu Asn Met Cys Gly Val Ala Cys Gly Arg Leu Asp Leu Cys
          195          200          205

Tyr Glu Ile Gly Phe Gly Gly Pro Trp Asp Val Ala Ala Gly Ala Leu
          210          215          220

Ile Leu Lys Glu Ala Gly Gly Phe Val Phe Asp Pro Ser Gly Asp Glu
          225          230          235          240

Phe Asp Leu Met Ala Gln Arg Met Ala Gly Ser Asn Gly His Leu Lys
          245          250          255

```

Asp Gln Phe Ile Lys Ala Leu Gly Asp Ala Ser  
260 265

<210> 9  
<211> 1090  
<212> DNA  
<213> Hordeum vulgare

<400> 9  
gcacgaggat aaactgagt agtcagtc tcttgaagtc gtgacgaaga acttcagaga 60  
ccacctcata cttggggagg aaggtggcct tattggagat tctttgtcag agtatctctg 120  
gtgcattgat ccttttagat gaacaacaaa ctttgcacat ggttacccca gcttttctgt 180  
atccattggg gttctttatc gaggcaagcc tgctgctgcc actgtggtgg aattttgtgg 240  
tgggcctatg tgctggagca ctctgacaat ttctgcatct tctggcaaag gtgcttattg 300  
taatgggcaa aaaattcatg tcagtccaac agaaaagggtg gaacagtctc ttctggtaac 360  
tgggttttga tatgaacatg atgatgcatg gctcaccaat ataaatttgt tcaaggaatt 420  
tactgatgtt agcaggggag tacgaaggct aggtctctgt gctgccgata tgtcccattg 480  
tggcttaggc attacagaag cctactggga atatcggctt aagccgtggg acatggctgc 540  
tggcgttctg atagttgaag aagctggtgg agtagtgaca cgcattggatg gtggggagtt 600  
tacagtcttt gatcgttctg ttcttgtttc caatggcggtt gttcatgata agcttttggg 660  
gcggtaccgg cctgctactg aagatcttaa gaagaaagga attgatttct ccttgtgggt 720  
taagcctgac aagtacccta ccgacttctg aatcacgctg ctcttcagct acttgttctc 780  
tgtctagcaa aaataaggat gtttttgcgt aacaaccatg tacttagact gacaatacat 840  
ttcaagacct ttctactcaa ccggtatgaa aattaaagcc gaactttaca taaaggagta 900  
gagctcgaat gagcttctca ctggattcct tttgctttga tcgaatgtat caggaagaaa 960  
tgtttgcaaa aggtgttgta tgcattgttc cagcctgttg tacttggaag aatataactg 1020  
ccaattttgt caatcatgga taatagcaag atctctcaag aagacatata ctaaaaaaaaa 1080  
aaaaaaaaaa 1090

<210> 10  
<211> 249  
<212> PRT  
<213> Hordeum vulgare

<400> 10  
His Glu Asp Lys Leu Ser Glu Ser Val Ile Leu Glu Val Val Thr Lys  
1 5 10 15  
Asn Phe Arg Asp His Leu Ile Leu Gly Glu Glu Gly Gly Leu Ile Gly  
20 25 30  
Asp Ser Leu Ser Glu Tyr Leu Trp Cys Ile Asp Pro Leu Asp Gly Thr  
35 40 45  
Thr Asn Phe Ala His Gly Tyr Pro Ser Phe Ser Val Ser Ile Gly Val  
50 55 60  
Leu Tyr Arg Gly Lys Pro Ala Ala Ala Thr Val Val Glu Phe Cys Gly  
65 70 75 80  
Gly Pro Met Cys Trp Ser Thr Arg Thr Ile Ser Ala Ser Ser Gly Lys  
85 90 95  
Gly Ala Tyr Cys Asn Gly Gln Lys Ile His Val Ser Pro Thr Glu Lys  
100 105 110  
Val Glu Gln Ser Leu Leu Val Thr Gly Phe Gly Tyr Glu His Asp Asp  
115 120 125  
Ala Trp Leu Thr Asn Ile Asn Leu Phe Lys Glu Phe Thr Asp Val Ser  
130 135 140  
Arg Gly Val Arg Arg Leu Gly Ser Ala Ala Ala Asp Met Ser His Val  
145 150 155 160

Gly Leu Gly Ile Thr Glu Ala Tyr Trp Glu Tyr Arg Leu Lys Pro Trp  
165 170 175

Asp Met Ala Ala Gly Val Leu Ile Val Glu Glu Ala Gly Gly Val Val  
180 185 190

Thr Arg Met Asp Gly Gly Glu Phe Thr Val Phe Asp Arg Ser Val Leu  
195 200 205

Val Ser Asn Gly Val Val His Asp Gln Leu Leu Glu Arg Ile Arg Pro  
210 215 220

Ala Thr Glu Asp Leu Lys Lys Lys Gly Ile Asp Phe Ser Leu Trp Phe  
225 230 235 240

Lys Pro Asp Lys Tyr Pro Thr Asp Phe  
245

<210> 11  
<211> 989  
<212> DNA  
<213> Zea mays

<400> 11  
ttcaggagct tggctctctt gaaactcgag tcaaagaact gtacatcgta ttgccattac 60  
aagtacagtg ctattgaact aaaaacatta ttgtttcttc ttgaaggacc ccccccccca 120  
aaaaaaaaatg atggctgctt tattatgggt gccaatggct ggtggtggtg cccttgggtgc 180  
agctcaaaag tcagtcgggt acttgtcagg ctgaaccac aacgagaagt cgatcccttt 240  
cttcttaagg tcttcagtag gagggccgat ccggtccaaa agctgtccac acagacaaca 300  
ctaagaacaa aacctgtcca tgaacgccac aaacaatatg ccaaattggt cacaacaaac 360  
aaacctgtcc atgaacaagt ccgttggaac caagaacaga gcgatcgaag accgtaaaact 420  
ctccaccgtc catgcgagtt accaccccac cagcttcttc tactatcagg acgccagcat 480  
gcacatccca tggcttaagt cggatttccc agtaagcttc tgtaatacca agtccaatgt 540  
gggacatgtc agcagcagca gacccgagcc ttcgcaactcc cctgctaattg tcagtaaatt 600  
ccttgaacag attcatattg gtcgtccagg catcatcgtg ttcatatcca aaacctgtga 660  
cgagaagtga ttgttccacc ttgtctgtct gactgacatg aatcctttgt ccaatataat 720  
aagctcctcc gccagcaaat ggaaaaattg ttcggtggtg ccaacacata aggcgcgccac 780  
aaaattctca ccacttgaa accacacggg ttttccagg aaagaacaac taatggcaca 840  
ggtaaacccg ggggtacat tggcaaagtt ccttgtctcc accaaagggg aattgccccca 900  
aaggtctcct gaaagggaat ctccaaaaag ggcgcctttt ccccccaatt aaaggggggc 960  
ttttaattct ttgggggaaa tctcaaaag 989

<210> 12  
<211> 136  
<212> PRT  
<213> Zea mays

<400> 12  
Met Cys Trp Thr Thr Arg Thr Ile Phe Pro Phe Ala Gly Gly Gly Ala  
1 5 10 15

Tyr Tyr Ile Gly Gln Arg Ile His Val Ser Gln Thr Asp Lys Val Glu  
20 25 30

Gln Ser Leu Leu Val Thr Gly Phe Gly Tyr Glu His Asp Asp Ala Trp  
35 40 45

Thr Thr Asn Met Asn Leu Phe Lys Glu Phe Thr Asp Ile Ser Arg Gly  
50 55 60

Val Arg Arg Leu Gly Ser Ala Ala Ala Asp Met Ser His Ile Gly Leu  
65 70 75 80

Gly Ile Thr Glu Ala Tyr Trp Glu Tyr Arg Leu Lys Pro Trp Asp Val  
85 90 95

His Ala Gly Val Leu Ile Val Glu Glu Ala Gly Gly Val Val Thr Arg  
100 105 110

Met Asp Gly Gly Glu Phe Thr Val Phe Asp Arg Ser Val Leu Val Ser  
115 120 125

Asn Gly Leu Val His Gly Gln Val  
130 135

<210> 13  
<211> 492  
<212> DNA  
<213> Zea mays

<220>  
<221> unsure  
<222> (351)

<220>  
<221> unsure  
<222> (442)

<220>  
<221> unsure  
<222> (485)

<400> 13  
agctccgagc gtcattctcc gccccgacat ttaaacccttg ctcccgacaa ccgcgcgcga 60  
ctctcccca atgctctcct ctctctctc caccactcg gccacctgc ccttccccgg 120  
octcgccctc gcaaacccta acccccgctc tcgctctctc cgctccgcg ccgcctcgcc 180  
cgtgtcgtcc gcggtcttga gcgcgagtg gcgccagccg atgagtaagg ttagggctc 240  
gttcgcgcgt ggggcggccg gccggagagc tgcggcagtg ggggagttgg cgacggagcg 300  
gctgggtggag gtggcgcaac gggcggcgga cgctgctggg gaggtgctca ngaagtactt 360  
ccgccagcgg gttgagatca tcgacaaaga ggaccacagt cctgttataa ttgcagatag 420  
aagaagcaga agaagcaatg gngtcagtta tactgaagag cttccctact caagccaatt 480  
ttggngaaga ga 492

<210> 14  
<211> 338  
<212> PRT  
<213> Zea mays

<400> 14  
Met Leu Ser Ser Ser Ser Ser Thr His Ser Asp Thr Ser Pro Phe Pro  
1 5 10 15

Gly Leu Ala Ser Ala Asn Pro Asn Pro Arg Ser Arg Leu Leu Arg Leu  
20 25 30

Arg Ala Ala Ser Pro Val Ser Ser Ala Val Leu Ser Ala Ser Gly Arg  
35 40 45

Gln Pro Met Ser Thr Val Arg Ala Ser Phe Ala Ala Gly Ala Ala Gly  
50 55 60

Arg Arg Ala Ala Ala Val Gly Glu Leu Ala Thr Glu Arg Leu Val Glu  
65 70 75 80

Val Ala Gln Arg Ala Ala Asp Ala Ala Gly Glu Val Leu Arg Lys Tyr  
85 90 95

Phe Arg Gln Arg Val Glu Ile Ile Asp Lys Glu Asp His Ser Pro Val  
100 105 110

Thr Ile Ala Asp Arg Glu Ala Glu Glu Ala Met Val Ser Val Ile Leu  
115 120 125

Lys Ser Phe Pro Thr His Ala Ile Phe Gly Glu Glu Asn Gly Trp Arg  
130 135 140

Cys Ala Glu Asn Ser Ala Asp Phe Val Trp Val Leu Asp Pro Ile Asp  
145 150 155 160

Gly Thr Lys Ser Phe Ile Thr Gly Lys Pro Leu Phe Gly Thr Leu Ile  
165 170 175

Ala Leu Leu His Asn Gly Lys Pro Val Ile Gly Val Ile Asp Gln Pro  
180 185 190

Ile Leu Arg Glu Arg Trp Ile Gly Val Asp Gly Lys Gln Thr Thr Leu  
195 200 205

Asn Gly Gln Glu Ile Ser Val Arg Ser Cys Asn Leu Leu Ala Gln Ala  
210 215 220

Tyr Leu Tyr Thr Thr Ser Pro His Leu Phe Glu Ala Asp Ala Glu Asp  
225 230 235 240

Ala Phe Ile Arg Val Arg Asn Lys Val Lys Val Pro Leu Tyr Gly Cys  
245 250 255

Asp Cys Tyr Ala Tyr Ala Leu Leu Ala Ser Gly Phe Val Asp Ile Val  
260 265 270

Val Glu Ser Gly Leu Lys Pro Tyr Asp Phe Leu Ser Leu Val Pro Val  
275 280 285

Ile Glu Gly Ala Gly Gly Ser Ile Thr Asp Trp Arg Gly Asp Lys Leu  
290 295 300

His Trp Pro Val Thr Ala Glu Ser Arg Pro Thr Ser Phe Asn Val Val  
305 310 315 320

Ala Ala Gly Asp Ala Arg Val His Lys Glu Ala Leu Asp Ala Leu Arg  
325 330 335

Trp Arg

<210> 15  
<211> 593  
<212> DNA  
<213> Oryza sativa

<400> 15  
gcacgagctt acaaaggtgg aacaatcact tctggtaact gggttttggtt atgaacatga 60  
tgatgcatgg gtgaccaaca taaatttggt caaggaatac acagacatta gcaggggagt 120  
acgaagacta ggttctgctg ctgctgacat gtcccacgtt gccctaggca ttacagaagc 180  
ctactgggaa taccgactta agccttgagg tatggctgct ggtgttctga tagttgaaga 240  
agctgggtggg atgggtgtcac gcatggatgg tggggagttt accgtctttg atcgttctgt 300  
ccttggtttcc aatgggtgtg tacatgatca gcttttggat cggattggcc ctgccacaga 360  
agatcttaag aagaaaggaa ttgatttctc cttgtgggtt aaacccgaca aataccctac 420  
cgacttttaa gttgaactcc tcaccagag ctattttata ctactagaag aaaagagaaa 480  
aacagaggat cttatgttaa aatgccatgt acttgactga atatttggtt attgaagtcc 540  
tttgactcaa aaaaaaaaaa aaaaaaaaaa tgcagggggg gccggtacac aat 593

<210> 16  
<211> 142  
<212> PRT  
<213> Oryza sativa

<400> 16  
 His Glu Leu Thr Lys Val Glu Gln Ser Leu Leu Val Thr Gly Phe Gly  
 1 5 10 15  
 Tyr Glu His Asp Asp Ala Trp Val Thr Asn Ile Asn Leu Phe Lys Glu  
 20 25 30  
 Tyr Thr Asp Ile Ser Arg Gly Val Arg Arg Leu Gly Ser Ala Ala Ala  
 35 40 45  
 Asp Met Ser His Val Ala Leu Gly Ile Thr Glu Ala Tyr Trp Glu Tyr  
 50 55 60  
 Arg Leu Lys Pro Trp Asp Met Ala Ala Gly Val Leu Ile Val Glu Glu  
 65 70 75 80  
 Ala Gly Gly Met Val Ser Arg Met Asp Gly Gly Glu Phe Thr Val Phe  
 85 90 95  
 Asp Arg Ser Val Leu Val Ser Asn Gly Val Val His Asp Gln Leu Leu  
 100 105 110  
 Asp Arg Ile Gly Pro Ala Thr Glu Asp Leu Lys Lys Lys Gly Ile Asp  
 115 120 125  
 Phe Ser Leu Trp Phe Lys Pro Asp Lys Tyr Pro Thr Asp Phe  
 130 135 140

<210> 17  
 <211> 1103  
 <212> DNA  
 <213> Glycine max

<400> 17  
 caattgcaat gttctcacag tgccattttc tctctcactc cccaattccc aatactacct 60  
 ttogtctcag agccatggcg cctcacagca cgctcttga actcaatgcg ttcgccgagg 120  
 tcggtaacaa agtcgccgat gctgccggag aagttatccg caaatacttc agaaaaaact 180  
 tcgacgttat tcacaaacat gatctcagtc cagtaaccat tgcagatcaa tctgctgagg 240  
 aggctatggg ttcaatcata ctgacaatt tcccttctca tgccatttac ggagaggaaa 300  
 atgggtggag gtgtgaagaa aagaatgctg attatgtttg ggtattagat cccatagatg 360  
 ggactaagag ctttattact gggaaacctg tatttggtag tctcgttgct cttctacaaa 420  
 atggcacacc aatccttggc ataattgatc aacctgtgtt aagagaaagg tggatcggga 480  
 tagcaggaaa gagaacctca ctgaacggac aagaaatatc tacacgcact tgtgcggacc 540  
 tttctcaagc atacctgtac accacaagcc cacatctgtt caatggagat gcagaagaag 600  
 cattcattcg tgttagaagc aaggtaaaat tccaattgta tggtcgcgac tgctatgcat 660  
 atgcactttt gtcttctggt tttgtggatc ttgttgttga gtctggctcg aagccatacg 720  
 attttcttgc attgattcct gttattgaag gcgctggagg tgtcataact gattggaaag 780  
 gagataaact gttttgggaa gcttctccac tttcaatcgc cacaagtttt aatgttgttg 840  
 ctgctggtga caaacagatt catcaacaag ctctagattc attgcagtgg aagtgatagc 900  
 ttgaattaat cttcagtgca aataatcttc tctgcaaatg gtcttgattc agatgttcct 960  
 aaggacatgt attaccgtac cattttctgg catttaagtt gaaaaccatg tactcagaat 1020  
 cttgaataag ttctgcaga aattaacctc tttgtctatt ggttggtaaa aaaagggggg 1080  
 gccgtacaaa tctccccgcc ccg 1103

<210> 18  
 <211> 295  
 <212> PRT  
 <213> Glycine max

<400> 18  
 Met Phe Ser Gln Cys His Phe Leu Ser His Ser Pro Ile Pro Asn Thr  
 1 5 10 15  
 Thr Phe Arg Leu Arg Ala Met Ala Pro His Ser Thr Pro Leu Glu Leu  
 20 25 30





```

gagagagaga tggggttggg tggacgggaa gaaaactacc ttaaatggac aagaaatata 600
tgtccgtcct tgcaatgtac tggagcaagc ttacttatat actacgagtc cacatctctt 660
tgaaggagat gctgaagatg cattcattcg tgtacgagac aaggtgaaag tcccattgta 720
tggctgtgat tgttatgctt atgctctcct ggcttctggt tttgtggatc ttgttgttga 780
atctggattg aagccatacg attttctctc gctggtaccg gtgattgaag gagctggggg 840
ctcaataact gattgggaag ggaacaagct ccactggcct gtctcttcgg aatctcggcc 900
aacaagtttc aacgtggtgg cagccggaga ttcccatgtc catgggcagg cctgggcagc 960
gttgcggtgg cgctagcctg cctgcagcac ggggcggctc ctattgttca tttagaaggc 1020
tgcaactgtt attcatctat ccaataaaaac tgagtctgta cgcttcctca gtgggtaaag 1080
caagttgttc acggtgcacc ctttactcaa taatgatcag tggtttcttg ttgtgtgtta 1140
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200
aaaaaaaaaa aaaaaacaaa aaaaaaaata aaaaaaaaaa aaaacccccg gggggggggc 1260
ggggaccaaa tttcccccata tttttttttt ttttaccocc ccccgagggg gtttttttta 1320
taaaacttct gaggggggaa aaaccggggg tttaccaaa taaatccct tgaacaaaaa 1380
ccccctttcc ccaagggggg taataaaaaa aagggccg 1418

```

```

<210> 20
<211> 324
<212> PRT
<213> Triticum aestivum

```

```

<400> 20
His Glu Thr Lys Pro Ser Leu Pro Tyr His Leu Arg Ser Pro Ser Leu
1 5 10 15
Leu Ala Thr Phe Ser Ser Ser Ala Ala Gly Arg Ala Cys Gly Ile Ala
20 25 30
Gly Arg Trp Met Gly Ser Val Arg Ala Ser Pro Ser Glu Ala Gly Gly
35 40 45
Trp Ala Val Ala Ala Ala Gly Lys Glu Gly Val Asp Met Glu Arg Leu
50 55 60
Val Ala Val Ala Gln Ser Ala Ala Asp Ala Ala Gly Glu Val Leu Arg
65 70 75 80
Lys Tyr Phe Arg Gln Arg Phe Glu Ile Ile Asp Lys Glu Asp His Ser
85 90 95
Pro Val Thr Ile Ala Asp Arg Glu Ala Glu Glu Ala Met Thr Ser Val
100 105 110
Ile Leu Lys Ser Phe Pro Thr His Ala Val Phe Gly Glu Glu Asn Gly
115 120 125
Trp Arg Cys Ala Glu Lys Ser Ala Asp Tyr Val Trp Val Leu Asp Pro
130 135 140
Ile Asp Gly Thr Lys Ser Phe Ile Thr Gly Lys Pro Leu Phe Gly Thr
145 150 155 160
Leu Ile Ala Leu Leu His Asn Gly Lys Pro Val Met Gly Ile Ile Asp
165 170 175
Gln Pro Ile Leu Arg Glu Arg Trp Val Gly Val Asp Gly Lys Lys Thr
180 185 190
Thr Leu Asn Gly Gln Glu Ile Ser Val Arg Pro Cys Asn Val Leu Glu
195 200 205
Gln Ala Tyr Leu Tyr Thr Thr Ser Pro His Leu Phe Glu Gly Asp Ala
210 215 220
Glu Asp Ala Phe Ile Arg Val Arg Asp Lys Val Lys Val Pro Leu Tyr
225 230 235 240

```

Gly Cys Asp Cys Tyr Ala Tyr Ala Leu Leu Ala Ser Gly Phe Val Asp  
245 250 255  
Leu Val Val Glu Ser Gly Leu Lys Pro Tyr Asp Phe Leu Ser Leu Val  
260 265 270  
Pro Val Ile Glu Gly Ala Gly Gly Ser Ile Thr Asp Trp Glu Gly Asn  
275 280 285  
Lys Leu His Trp Pro Val Ser Ser Glu Ser Arg Pro Thr Ser Phe Asn  
290 295 300  
Val Val Ala Ala Gly Asp Ser His Val His Gly Gln Ala Leu Ala Ala  
305 310 315 320  
Leu Arg Trp Arg

<210> 21  
<211> 273  
<212> PRT  
<213> Lycopersicon esculentum

<400> 21  
Met Ala Arg Asn Gly Ser Leu Glu Glu Phe Leu Gly Val Ala Val Asp  
1 5 10 15  
Ala Ala Lys Arg Ala Gly Glu Ile Ile Arg Lys Gly Phe His Glu Thr  
20 25 30  
Lys His Val Val His Lys Gly Gln Val Asp Leu Val Thr Glu Thr Asp  
35 40 45  
Lys Ala Cys Glu Asp Leu Ile Phe Asn His Leu Lys Gln His Phe Pro  
50 55 60  
Ser His Lys Phe Ile Gly Glu Glu Thr Ser Ala Ala Thr Gly Asp Phe  
65 70 75 80  
Asp Leu Thr Asp Glu Pro Thr Trp Ile Val Asp Pro Val Asp Gly Thr  
85 90 95  
Thr Asn Phe Val His Gly Phe Pro Ser Val Cys Val Ser Ile Gly Leu  
100 105 110  
Thr Ile Gly Lys Ile Pro Thr Val Gly Val Val Tyr Asp Pro Ile Ile  
115 120 125  
Asp Glu Leu Phe Thr Gly Ile Asn Gly Lys Gly Ala Tyr Leu Asn Gly  
130 135 140  
Lys Pro Ile Lys Val Ser Ser Gln Ser Glu Leu Val Lys Ser Leu Leu  
145 150 155 160  
Gly Thr Glu Val Gly Thr Thr Arg Asp Asn Leu Thr Val Glu Thr Thr  
165 170 175  
Thr Arg Arg Ile Asn Asn Leu Leu Phe Lys Val Arg Ser Leu Arg Met  
180 185 190  
Cys Gly Ser Cys Ala Leu Asp Leu Cys Trp Val Ala Cys Gly Arg Leu  
195 200 205  
Glu Leu Phe Tyr Leu Ile Gly Tyr Gly Gly Pro Trp Asp Val Ala Gly  
210 215 220

Gly Ala Val Ile Val Lys Glu Ala Gly Gly Val Leu Phe Asp Pro Ser  
225 230 235 240

Gly Ser Glu Phe Asp Ile Thr Ser Gln Arg Val Ala Ala Thr Asn Pro  
245 250 255

His Leu Lys Glu Ala Phe Val Glu Ala Leu Gln Leu Ser Glu Tyr Val  
260 265 270

Ser

<210> 22

<211> 268

<212> PRT

<213> Lycopersicon esculentum

<400> 22

Met Ala Gln Asn Gly Ser Val Glu Gln Phe Leu Asp Val Ala Val Glu  
1 5 10 15

Ala Ala Lys Lys Ala Gly Glu Ile Ile Arg Glu Gly Phe Tyr Lys Thr  
20 25 30

Lys His Val Glu His Lys Gly Met Val Asp Leu Val Thr Glu Thr Asp  
35 40 45

Lys Ala Cys Glu Asp Phe Ile Phe Asn His Leu Lys Gln Arg Phe Pro  
50 55 60

Ser His Lys Phe Ile Gly Glu Glu Thr Thr Ala Ala Cys Gly Asn Phe  
65 70 75 80

Glu Leu Thr Asp Glu Pro Thr Trp Ile Val Asp Pro Leu Asp Gly Thr  
85 90 95

Thr Asn Phe Val His Gly Phe Pro Phe Val Cys Val Ser Ile Gly Leu  
100 105 110

Thr Ile Glu Lys Lys Pro Thr Val Gly Val Val Tyr Asn Pro Ile Ile  
115 120 125

Asp Glu Leu Phe Thr Gly Ile Asp Gly Lys Gly Ala Phe Leu Asn Gly  
130 135 140

Lys Pro Ile Lys Val Ser Ser Gln Ser Glu Leu Val Lys Ala Leu Leu  
145 150 155 160

Ala Thr Glu Ala Gly Thr Asn Arg Asp Lys Leu Val Val Asp Ala Thr  
165 170 175

Thr Gly Arg Ile Asn Ser Leu Leu Phe Lys Val Arg Ser Leu Arg Met  
180 185 190

Cys Gly Ser Cys Ala Leu Asn Leu Cys Gly Val Ala Cys Gly Arg Leu  
195 200 205

Asp Leu Phe Tyr Glu Leu Glu Phe Gly Gly Pro Trp Asp Val Ala Gly  
210 215 220

Gly Ala Val Ile Val Lys Glu Ala Gly Gly Phe Val Phe Asp Pro Ser  
225 230 235 240

Gly Ser Glu Phe Asp Leu Thr Ala Arg Arg Val Ala Ala Thr Asn Ala  
245 250 255

His Leu Lys Asp Ala Phe Ile Lys Ala Leu Asn Glu  
260 265

<210> 23  
<211> 287  
<212> PRT  
<213> Synechocystis sp.

<400> 23  
Met Thr Ser Ala Gln Lys Pro Val Phe Ser Pro Ser Asp Leu Gln Thr  
1 5 10 15  
Trp Leu Glu Ile Ala Thr Glu Ala Val Leu Ala Ala Gly Ala Glu Ile  
20 25 30  
Phe Ser Leu Trp Gly Lys Val Gln Gln Ile Gln Glu Lys Gly Arg Ala  
35 40 45  
Gly Asp Leu Val Thr Glu Ala Asp Arg Gln Ala Glu Ala Ile Ile Leu  
50 55 60  
Glu Ile Ile Lys Arg Arg Cys Pro Asp His Ala Ile Leu Ala Glu Glu  
65 70 75 80  
Ser Gly Gln Leu Gly Gln Val Asp Asn Pro Phe Cys Trp Ala Ile Asp  
85 90 95  
Pro Leu Asp Gly Thr Thr Asn Phe Ala His Ser Tyr Pro Val Ser Cys  
100 105 110  
Val Ser Ile Gly Leu Leu Ile Gln Asp Ile Pro Thr Val Gly Val Val  
115 120 125  
Tyr Asn Pro Phe Arg Gln Glu Leu Phe Arg Ala Ala Thr Ser Leu Gly  
130 135 140  
Ala Thr Leu Asn Arg Arg Pro Ile Gln Val Ser Thr Thr Ala Ser Leu  
145 150 155 160  
Asp Lys Ser Leu Leu Val Thr Gly Phe Ala Tyr Asp Arg Val Lys Thr  
165 170 175  
Leu Asp Asn Asn Tyr Pro Glu Phe Cys Tyr Leu Thr His Leu Thr Gln  
180 185 190  
Gly Val Arg Arg Ser Gly Ser Ala Ala Ile Asp Leu Ile Asp Val Ala  
195 200 205  
Cys Gly Arg Leu Asp Gly Tyr Trp Glu Arg Gly Ile Asn Pro Trp Asp  
210 215 220  
Met Ala Ala Gly Ile Val Ile Val Arg Glu Ala Gly Gly Ile Val Ser  
225 230 235 240  
Ala Tyr Asp Cys Ser Pro Leu Asp Leu Ser Thr Gly Arg Ile Leu Ala  
245 250 255  
Thr Asn Gly Lys Ile His Gln Glu Leu Ser Gln Ala Leu Ala Ala Thr  
260 265 270  
Pro Gln Trp Phe Gln Gln Tyr Ala Ala Ala Arg Ala Gln Lys Ile  
275 280 285  
<210> 24  
<211> 267

<212> PRT  
 <213> Synechocystis sp.

<400> 24

```

Met Leu Pro Glu Val Glu Gln Arg Leu Phe Ile Ala Gln Gln Leu Ala
 1           5           10           15

Ala Val Ser Gly Glu Ile Leu Ile Gln Tyr Phe Arg Arg Ser His Leu
          20           25           30

Gln Gly Gly Thr Lys Ile Asp Gln Val Ser Ala Ile Val Thr Gln Ala
          35           40           45

Asp Glu Glu Ala Glu Gln Ala Met Val Asp Leu Ile Gln Ala Gln Phe
          50           55           60

Pro Gln Asp Gly Val Ile Arg Glu Glu Gly Lys Asn Ile Ala Gly Lys
          65           70           75           80

Ser Gly Tyr Thr Trp Val Leu Asp Pro Ile Asp Gly Thr Ser Ser Phe
          85           90           95

Val Arg Gly Leu Pro Ile Phe Ala Thr Leu Ile Gly Leu Val Asp Ala
          100          105          110

Asp Met Arg Pro Val Leu Gly Ile Ala His Gln Pro Ile Ser Gly Asp
          115          120          125

Arg Trp Gln Gly Val Gln Gly Glu Gln Ser Asn Val Asn Gly Ile Pro
          130          135          140

Leu Val Asn Pro Tyr Lys Ala Ser Glu Ile Asn Leu Thr Ala Ala Cys
          145          150          155          160

Ile Val Ser Thr Thr Pro Leu Met Phe Thr Thr Pro Val Gln Gln Gln
          165          170          175

Lys Met Ala Asp Ile Tyr Arg Gln Cys Gln Arg Thr Ala Phe Gly Gly
          180          185          190

Asp Cys Phe Asn Tyr Leu Ser Ala Ala Ser Gly Trp Thr Ala Met Pro
          195          200          205

Leu Val Ile Val Glu Ala Asp Leu Asn Phe Tyr Asp Phe Cys Ala Leu
          210          215          220

Ile Pro Ile Leu Thr Gly Ala Asn Tyr Cys Phe Thr Asp Trp Gln Gly
          225          230          235          240

Lys Glu Leu Thr Pro Glu Ser Thr Glu Val Val Ala Ser Pro Asn Pro
          245          250          255

Lys Leu His Ser Glu Ile Leu Ala Phe Leu Gln
          260          265

```